Leading Pharmacology Journals

Publications of the American Society for Pharmacology and Experimental Therapeutics, Inc.

The Journal of Pharmacology and Experimental Therapeutics

Editor: John A. Harvey, Ph.D.

JPET is respected the world over as one of the leading research journals in the field of pharmacology. Readers find broad coverage of all aspects of the interactions of chemicals with biological systems, including autonomic, behavioral, cardiovascular, cellular, clinical, developmental, gastrointestinal, immuno-, neuro-, pulmonary, and renal pharmacology, as well as analgesics, drug abuse, metabolism and disposition, chemotherapy, and toxicology. *Monthly*

Drug Metabolism and Disposition: the biological fate of chemicals

Editor: Vincent G. Zannoni, Ph.D.

Drug Metabolism and Disposition publishes in vitro and in vivo experimental results that bring readers significant and original information on xenobiotic metabolism and disposition, including metabolism of all pharmacologic agents or drugs and environmental chemicals, reactants and preservatives. The areas covered are: pharmacokinetics, pharmacodynamics and mechanisms, genetic, nutritional, or hormonal factors affecting the biological fate of chemicals, toxicological consequences of xenobiotic metabolism. *Bimonthly*

Pharmacological Reviews

Editor: Robert E. Stitzel, Ph.D.

Pharmacological Reviews is a showcase for important review articles in your field, featuring longer papers on topics of high current interest. The areas covered in review papers have included biochemical and cellular pharmacology, drug metabolism and disposition, renal pharmacology, neuropharmacology, behavioral pharmacology, clinical pharmacology, and toxicology. No library serving the pharmacologic community should be without a subscription. *Quarterly*

Discounts available to members on all ASPET publications.

SAVE 10% when ordering two

SAVE 15% when ordering three

SAVE 20% when ordering all four

Molecular Pharmacology

Editor: T. Kendall Harden, Ph.D.

The papers published in **Molecular Pharmacology** are on the cutting edge of research on drug action and selective toxicity at the molecular level. Original applications of biochemistry, biophysics, genetics, and molecular biology are juxtaposed with innovative pharmacologic research to elucidate basic problems in pharmacology and toxicology, including such areas as molecular mechanisms involved in drug receptor-effector coupling, xenobiotic metabolism, and antibiotic and anticancer drug action. *Monthly*

	0/yr	Institutional \$340/yr			
New Subscripti		Canada, also add 7% GST.) Renewal			
3 yrs	2 yrs	1 yr			
Drug Metabolism	and Disposition (b	imonthly)			
Individual \$85		Institutional \$140/yr			
(Please add \$20/y	add \$20/yr outside the US; in Canada, also add 7% GST.)				
New Subscripti	on	Renewal			
3 yrs	2 yrs	1 yr			
Molecular Pharm	acology (monthly)				
Individual \$10	5/yr	Institutional \$230/yr			
(Please add \$30/y	ase add \$30/yr outside the US; in Canada, also add 7% GST				
New Subscripti	on	Renewal			
3 yrs	2 yrs	1 yr			
New Subscripti 3 yrs Payment options:	2 yrs	Renewal 1 yr is & Wilkins) Bill me			
	asterCard Am				
Card #	Exp. date				
Signature		sales tax. Subscriptions outside			

toll-free 1-800-638-6423

(from anywhere in US or Canada

P.O. Box 23291

Baltimore, MD 21203-9990

J3046S ZPTT

An important resource for everyone involved in research on the metabolism of drugs and chemicals

DRUG METABOLISM AND DISPOSITION

The Biological Fate of Chemicals


Editor: Vincent G. Zannoni, PhD, University of Michigan, Ann Arbor, Michigan

DRUG METABOLISM AND DISPOSITION publishes *in vitro* and *in vivo* experimental results that bring readers significant and original information on xenobiotic metabolism and disposition, including metabolism of all pharmacologic agents or drugs and environmental chemicals, reactants, and preservatives. All papers are refereed to ensure a high standard of publication. The areas covered are:

- pharmacokinetics
- pharmacodynamics
- genetic, nutritional, and hormonal factors affecting the biological fate of chemicals
- toxicological consequences of xenobiotic metabolism

This journal should be a standard reference in all pharmacology and toxicology departments. It is also a valuable resource for all medicinal chemists involved in designing drugs and all biochemists involved with drug metabolism.

Bimonthly



1 - amintion:	POL	Enter my subscription:	,

Ed! Enter my subscription.				
$\label{eq:continuous} \textbf{Avoid future rate increases and ensure uninterrupted service} - \textbf{enter} \\ \textbf{your multiyear subscription today!}$	Payment options: ☐ Check enclosed ☐ VISA	☐ Bill me ☐ MasterCard	☐ American Express	
Drug Metabolism and Disposition (bimonthly)				
☐ Individual: \$85/yr ☐ Institutions: \$140/yr (Please add \$20.00 outside the U.S.; in Canada, also add 7% GST.)	card *			
\square New Subscription \square Renewal \square 3 yrs \square 2 yrs \square 1 yr	signature/P.O. •			
	CA, MD and PA subscribers must add state sales tax. Subscriptions from outside the US and Canada must be prepaid, in US dollars only. Rates valid for orders received before October 31, 1993.			
name	Please allow 8 weeks for delivery of your first issue. Surface mail delivery to countries outside the US may take up to 16 weeks. Airmail rates available upon			
address	request.			
city/state/zip				

Williams & Wilkins

DMD 54104

P.O. Box 23291 Baltimore, Maryland 21203-9990 Broadway House 2-6 Fulham Broadway London SW6 1AA England

J3009S ZDMD



Zinc Protoporphyrin IX

NEW

$$H_{2}C = HC$$
 N
 $CH_{2}CH_{2}CO_{2}$
 $CH_{2}CH_{2}CO_{2}$
 $CH_{2}CH_{2}CO_{2}$
 $CH_{2}CH_{2}CO_{2}$
 $CH_{2}CH_{2}CO_{2}$

Inhibitor of hepatic heme oxygenase.

Cat. No. Z-102 Verma et al. "Carbon monoxide: A putative neural messenger." Science 259, 381 (1993).

N^G-Monomethyl-L-arginine acetate

NO synthetase inhibitor. Cat. No. M-125 Olken et al. Biochem. Biophys. Res. Commun. 177(2), 828 (1991).

S-Nitroso-N-acetylpenicillamine (SNAP)

Potent vasodilator; releases nitric oxide when administered in vivo. Cat. No. N-152 Schaeffer et al. J. Pharmacol. Exp. Ther. 260(1), 286 (1992).

OTHER FEATURED RBI PRODUCTS -

Bav K 8644

(+/-) Ca²⁺ slow channel agonist. Cat. No. B-112

S(-) Ca2+ channel activator. Cat. No. B-133

R(+) Ca²⁺ channel blocker. Cat. No. B-132

DOI HCI

(+/-) Potent and selective 5HT₂/5HT_{1C} serotonin agonist that crosses the blood brain barrier.

Cat. No. D-101

R(-) More potent enantiomer.

Cat. No. D-153

S(+) Less potent enantiomer.

Cat. No. D-154

Highly selective, non-peptide δ-opioid antagonist. Cat. No. N-115

CGP-23996

Naltrindole HCI

A non-reducible analog of somatostatin suitable for

iodination; the radioiodinated molecule can be used in binding assays for somatostatin receptors.

Cat. No. C-176

Thiobutabartibal sodium salt (Inactin®*)

Long-lasting animal anesthetic. Cat. No. T-133 *A registered trademark of Byk-Gulden

Please call or write for our 1992/93 Catalog/Handbook listing over 800 pharmacologically active compounds.



One Strathmore Road, Natick, MA 01760-2418 USA 800-736-3690 • 508-651-8151 • Fax 508-655-1359